Atlas Trials

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Clinical trial NCT02677896 · COMPLETED

Trial details

NCT number
NCT02677896
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Hormone Sensitive Prostate Cancer
Start date
2016-03-09
Primary completion
2018-10-14
Enrollment
1150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.